Linnea Olsen, along with many other long-term ALK-positive lung cancer survivors, participated in clinical trials at several junctures in treatment. Linnea participated in a trial of Crizotinib, the first treatment for ALK-positive lung cancer. She joined 5 more clinical trials over the course of her illness. By enrolling in clinical trials, she was able to get advanced treatments before they were approved for general medical use.

Read More